# 67

Furuno T<sup>1</sup>, Kakizaki H<sup>2</sup>, Tanaka H<sup>1</sup>, Mitsui T<sup>1</sup>, Kitta T<sup>1</sup>, Matsui M<sup>3</sup>, Nonomura K<sup>1</sup>

1. Department of Urology, Hokkaido University Graduate School of Medicine, 2. Department of Urology, Asahikawa Medical College, 3. Division of Neuronal Network, Institute of Medical Science, University of Tokyo

# ENHANCED INHIBITORY EFFECTS OF BETA-ADRENOCEPTOR AGONIST ON CHOLINERGIC MICTURITION CONTRACTIONS IN MUSCARINIC M2 RECEPTOR KNOCKOUT MICE.

# Hypothesis / aims of study

Muscarinic  $M_2$  receptor is coupling with  $G_i$  to inhibit adenylyl cyclase and decreases cAMP levels, and betaadrenoceptor is coupling with  $G_s$  to activate adenylyl cyclase and increases intracellular cAMP levels. Increase of cAMP mediates relaxation of the bladder smooth muscle. Thus,  $M_2$  receptor and beta-adrenoceptor are counteracting each other via adenylyl cyclase activity. A previous in vitro study showed an increased relaxant action of isoproterenol (beta-adrenoceptor agonist) on muscarinic agonist-induced contraction of the bladder smooth muscle from  $M_2$  receptor knockout mice [1]. This result suggests that cholinergic contractile mechanism in the detrusor smooth muscle involves  $M_2$  receptor-mediated inhibition of the relaxant effects of beta-adrenoceptor activation. The aim of this study is to investigate the relationship between  $M_2$  receptor and beta-adrenoceptor in bladder functions in vivo.

#### Study design, materials and methods

Eight to 10-week male muscarinic  $M_2$  receptor knockout mice (M<sub>2</sub>KO) and wild type C57BL/6 (WT) were used in this study. A mutant mouse line was backcrossed to C57BL/6 at least 10 generations and established as a congenic line. Conscious filling cystometry was performed via cystostomy catheter surgically inserted on the day with isoflurene inhalation. After 1 to 2 hour wait, saline of room temperature (1.5ml/h) was infused and bladder pressure was measured. To evaluate the isoproterenol effects, after baseline measurement, vehicle (saline), 10, 100 and 1000  $\mu$ g isoproterenol was cumulatively injected subcutaneously (WT n=10, M<sub>2</sub>KO n=11). To evaluate the contribution of cholinergic and purinergic component, the effects of atropine (1 mg/kg s.c.) and additive alpha, beta-methylene-ATP (abMeATP, 3 mg/kg i.p) on micturition contraction were investigated in 5 WT mice. The effects of isoproterenol on purinergic component of contraction were evaluated. The differences between WT and M<sub>2</sub>KO were analyzed.

#### Results

There was no difference between WT and  $M_2$ KO on baseline cystometry. Micturition pressure after administration of isoproterenol 100 and 1,000 µg/kg were significantly lower in  $M_2$ KO than in WT (100 µg/kg: WT 26.3+-1.6 cmH<sub>2</sub>O vs.  $M_2$ KO 21.8+-1.2 cmH<sub>2</sub>O, p<0.05; 1,000 µg/kg: WT 24.7+-1.5 cmH<sub>2</sub>O vs.  $M_2$ KO 18.0+-1.0 cmH<sub>2</sub>O, p<0.01; see figure 1). After administration of maximum dose isoproterenol, residual volume were higher (1000 µg/kg: WT 10.4+-1.6 µl vs.  $M_2$ KO 15.1+-1.4 µl, p<0.05) and voiding efficacy were lower (1000 µg/kg: WT 86.9+-2.2 % vs.  $M_2$ KO 79.5+-1.7 %, p<0.05) in  $M_2$ KO than in WT. Other cystometric parameters had no significant difference between WT and  $M_2$ KO.

Biphasic and rhythmic micturition contractions were observed during conscious filling cystometry and atropine (1 mg/kg s.c.) gradually inhibited the second phase contractions (before atropine: 30.8+-1.3 cmH<sub>2</sub>O) in each mouse to undetectable level, whereas there was no significant effect on the initial phase contraction (before atropine: 19.0+-0.7 cmH<sub>2</sub>O); after atropine: 16.8+-0.8 cmH<sub>2</sub>O); see figure 2). Additive administration of abMeATP completely abolished the rhythmic contractions after transient bladder pressure increase in 4 of 5 WT mice (figure 2). Thus the initial contraction was ATP sensitive and the second phase contraction was atropine sensitive. M<sub>2</sub>KO as well as wild type mice exhibited biphasic micturition contractions during cystometry.

Isoproterenol (1,000  $\mu$ g/kg s.c.) had no significant effect on the amplitude of the initial phase contraction, but clearly inhibited the second phase contraction in both WT and M<sub>2</sub>KO (figure 3). However, this inhibitory effect of isoproterenol on the second phase contraction was more prominent in M<sub>2</sub>KO than in WT (isoproterenol 1,000  $\mu$ g/kg: WT 22.5+-1.4 cmH<sub>2</sub>O vs. M<sub>2</sub>KO 14.6+-1.5 cmH<sub>2</sub>O, p<0.01; figure 3). These results revealed that inhibitory effects of isoproterenol on cholinergic micturition contractions were enhanced in the absence of muscarinic M<sub>2</sub> receptor.

# Interpretation of results

Primal bladder function in muscarinic  $M_2$  receptor knockout mice is identical to wild type, but the inhibitory effect of beta-agonist, isoproterenol on the second phase cholinergic detrusor contraction is more pronounced in muscarinic  $M_2$  receptor knockout mice.

# Concluding message

Although the specific functions of each muscarinic receptor subtype had been mainly investigated in vitro, the present study showed the enhanced inhibitory action of isoproterenol on cholinergic micturition contraction in muscarinic  $M_2$  receptor knockout mice in vivo. This result suggests that cholinergic contractile mechanism of micturition involves  $M_2$  receptor-mediated inhibition of the relaxant effects caused by beta-adrenoceptor activation. Suitable balance between  $M_2$  receptor and beta-adrenoceptor via the change of adenylyl cyclase activity may play a essential role for normal bladder functions.

<u>References</u> (1) JPET 305: 106-113, 2003



Figure 2: Effects of atropine and abMeATP on micturition in wild type. Atropine inhibited second phase contraction (left) and additive abMeATP suppressed rhythmic micturition after transient increase of bladder pressure (right).



Figure 3: Cumulative dose of isoproterenol inhibited second phase cholinergic contraction and this effect is more pronounced in  $M_2KO$ .

FUNDING: Pfizer, Pharmacia, The New Energy and Industrial Technology Development Organization (NEDO) of Japan, The Ministry of Education, Culture, Sports, Science and Technology (MEXT) DISCLOSURES: NONE

ANIMAL SUBJECTS: This study followed the guidelines for care and use of laboratory animals and was approved by Hokkaido University Institutional Animal Care and Use Committee